ArticlebioRxiv : the preprint server for biology2026
Topoisomerase I inhibition suppresses nuclear blebbing via RNA Pol II stalling and nuclear stiffening.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Abnormal nuclear blebbing occurs in many human diseases and causes nuclear rupture and dysfunction. Nuclear blebbing is caused by chromatin motion via RNA Pol II transcriptional activity and nuclear mechanical weakening. Camptothecin, a topoisomerase I inhibitor, rapidly suppresses nuclear blebbing within hours. We find that camptothecin does not decrease RNA Pol II phosphorylation, but does decrease newly synthesized RNA, likely by stalling RNA Pol II. However, camptothecin treatment suppresses nuclear blebbing more drastically than inhibition of transcription activity by alpha amanitin, suggesting a second mechanism of nuclear blebbing suppression. Dual micromanipulation nuclear force measures revealed camptothecin treatment increased chromatin-based nuclear stiffness but not lamin-based strain stiffening. Thus, inhibition of topoisomerase I via camptothecin drastically suppresses nuclear blebbing by both stalling RNA Pol II and increasing chromatin-based nuclear stiffness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.